CD274 and urinary bladder cancer: While patients with such tumors are often excluded from clinical trials of novel agents such as immune checkpoint inhibitors, the recent FDA-approvals of anti-PD-L1 and anti-PD1 antibodies for patients with bladder cancer should facilitate future biomarker studies to determine how the lineage plasticity observed in other histologic variants impacts the tumor microenvironment.